Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Update
by Scott Moore · The Cerbat GemOruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totaling 4,522,980 shares, an increase of 24.1% from the March 15th total of 3,644,487 shares. Approximately 12.1% of the shares of the company are short sold. Based on an average trading volume of 900,965 shares, the short-interest ratio is presently 5.0 days.
Trending Headlines about Oruka Therapeutics
Here are the key news stories impacting Oruka Therapeutics this week:
- Positive Sentiment: Multiple high‑profile analyst upgrades and price‑target increases (Wedbush to an $85 target/”outperform”, BTIG to $78, Guggenheim/UBS/Stifel also raising targets) are driving optimism and buying interest. Read More.
- Positive Sentiment: HC Wainwright reiterated a Buy and published multi‑quarter and FY forecasts while keeping a ~$70 target, providing institutional research support that reinforces the upgrade momentum. Read More.
- Positive Sentiment: Aggregate analyst coverage has shifted the consensus toward a “Moderate Buy” with an average price target near the high‑$70s, which helps justify further upside from investors focused on price‑target momentum. Read More.
- Neutral Sentiment: An insider (Joana Goncalves) sold 7,000 shares under a pre‑arranged Rule 10b5‑1 plan; because the sale was disclosed and pre‑planned it is less likely to signal new negative company information, though it increases float supply. Read More.
- Negative Sentiment: Consensus and firm forecasts still show sustained losses (consensus FY ~‑$3.41 EPS; HC Wainwright FY2027 ~‑$3.55), meaning valuation is tethered to clinical progress for ONCT‑01 and future commercial proof — a risk that can cap multiple expansion despite bullish price targets. Read More.
Insider Activity at Oruka Therapeutics
In other news, insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $66.12, for a total transaction of $462,840.00. Following the completion of the transaction, the insider owned 33,377 shares of the company’s stock, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 23,765 shares of company stock worth $1,089,745. Corporate insiders own 24.69% of the company’s stock.
Institutional Investors Weigh In On Oruka Therapeutics
Hedge funds have recently bought and sold shares of the business. Royal Bank of Canada lifted its stake in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in Oruka Therapeutics in the 4th quarter worth about $37,000. PNC Financial Services Group Inc. purchased a new stake in Oruka Therapeutics in the 3rd quarter worth about $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in Oruka Therapeutics in the 4th quarter worth about $67,000. Finally, Russell Investments Group Ltd. purchased a new stake in Oruka Therapeutics in the 3rd quarter worth about $43,000. 56.44% of the stock is owned by hedge funds and other institutional investors.
Oruka Therapeutics Stock Performance
Shares of NASDAQ:ORKA traded up $1.42 during midday trading on Thursday, reaching $66.97. The company had a trading volume of 1,060,928 shares, compared to its average volume of 662,711. Oruka Therapeutics has a 1-year low of $8.36 and a 1-year high of $67.94. The firm has a market cap of $3.32 billion, a price-to-earnings ratio of -36.01 and a beta of -0.54. The company has a fifty day simple moving average of $41.37 and a two-hundred day simple moving average of $33.23.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. Analysts expect that Oruka Therapeutics will post -3.41 EPS for the current year.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the company. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. UBS Group increased their price target on Oruka Therapeutics from $50.00 to $75.00 and gave the stock a “buy” rating in a research note on Monday, April 6th. BTIG Research increased their price target on Oruka Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Monday. Wedbush increased their price target on Oruka Therapeutics from $45.00 to $85.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Guggenheim reissued a “buy” rating and issued a $125.00 price target on shares of Oruka Therapeutics in a research note on Monday. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $78.90.
Check Out Our Latest Research Report on ORKA
About Oruka Therapeutics
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.